Evidence map›Paper›PMID 41972196›Full record

ArticleEFSA journal. European Food Safety Authority2026

Dietary exposure to lycopene from background diet, novel foods and food additive use in the European population.

European Food Safety Authority (EFSA), Bruno Dujardin, Zsuzsanna Horváth, Alexandra Tard

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

European Food Safety Authority (EFSA)
Bruno Dujardin
Zsuzsanna Horváth
Alexandra Tard

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2023, EFSA adopted a scientific opinion on the safety of yellow/orange tomato extract as a novel food pursuant to Regulation (EU) 2015/2283, concluding that its safe use could not be established under the proposed conditions and estimated intakes could lead to an exceedance of the acceptable daily intake for lycopene when considering combined exposure from natural occurrence and food additive uses. Consequently, EFSA was requested to carry out a dietary exposure assessment of lycopene considering combined intakes from the background diet and from its authorised uses as food additive and as novel food. For the refined scenarios, use level data were collected from industry for food additive and novel food uses, while occurrence data for naturally occurring lycopene were extracted from the literature. Food consumption data were obtained from EFSA's Comprehensive European Food Consumption Database. Five exposure scenarios were assessed: a regulatory maximum level scenario, a refined non-brand-loyal scenario, a food supplements consumers only scenario, a scenario for infants and toddlers consuming foods for special medical purposes, and a scenario for infants below 16 weeks consuming such foods. In the regulatory maximum level scenario, the highest combined mean and 95th percentile exposures were observed in toddlers with 1.2 and 2.52 mg/kg bw per day, respectively. In the refined non-brand-loyal scenario, highest mean exposure was in toddlers at 0.36 mg/kg bw per day and P95 exposure in infants at 0.97 mg/kg bw per day. Naturally occurring lycopene was the predominant contributor to total exposure in the refined non-brand-loyal scenario. In the scenario for food supplements consumers, novel food use in food supplements contributed significantly to the background exposure, leading to a twofold increase. Novel food use in foods for special medical purposes for infants and toddlers contributed to much smaller extent compared to food supplements in the previous scenario.

Indexed as

exposure assessmentfood additiveslycopenenatural occurrencenovel foods

Identifiers

PMID41972196
PMCPMC13062937

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.